IOVA
IOVANCE BIOTHERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$8.48
−11.30%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 325.0M | 263.5M | 164.1M | 1.2M | — |
| Cost of Revenue | 167.7M | 173.2M | 124.0M | 10.8M | — |
| Gross Profit | 157.3M | 90.3M | 40.1M | (9.6M) | — |
| Operating Expenses | |||||
| R&D Expense | 267.7M | 300.3M | 282.3M | 344.1M | 294.8M |
| SG&A Expense | 149.2M | 152.3M | 153.0M | 106.9M | 104.1M |
| General & Admin Expense | — | — | — | — | 104.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 36.6M | 35.9M | — | — | — |
| Total Operating Expenses | 453.5M | 488.5M | 435.4M | 451.0M | 398.9M |
| Cost and Expenses | 621.1M | 661.7M | 559.3M | 461.7M | 398.9M |
| Operating Income (EBIT) | (296.2M) | (398.2M) | (395.3M) | (460.6M) | (398.9M) |
| Non-Operating | |||||
| Interest Income | 7.5M | 10.3M | 20.3M | 13.0M | 3.0M |
| Interest Expense | — | — | — | — | 3.0M |
| Net Interest Income | 7.5M | 10.3M | 20.3M | 13.0M | — |
| Other Non-Op Income/Expense | 2.4M | 5.2M | 20.3M | 13.0M | 3.0M |
| Non-Operating Income (excl Interest) | — | — | (20.3M) | (13.0M) | (6.0M) |
| EBT (Pre-Tax Income) | (293.8M) | (393.0M) | (375.0M) | (447.5M) | (395.9M) |
| Income Tax Expense | (4.3M) | (2.1M) | (2.8M) | (3.5M) | — |
| Bottom Line | |||||
| Net Income | (289.5M) | (391.0M) | (372.2M) | (444.0M) | (395.9M) |
| Earnings from Cont. Ops | (289.5M) | (391.0M) | (372.2M) | (444.0M) | (395.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (289.5M) | (391.0M) | (372.2M) | (444.0M) | (395.9M) |
| Per Share | |||||
| Basic EPS | ($0.73) | ($1.09) | ($1.28) | ($1.89) | ($2.49) |
| Diluted EPS | ($0.73) | ($1.09) | ($1.28) | ($1.89) | ($2.49) |
| Revenue Per Share | $0.72 | $0.74 | $0.57 | $0.01 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 450.2M | 357.3M | 289.9M | 235.1M | 159.3M |
| Diluted Shares Outstanding | 450.2M | 357.3M | 289.9M | 235.1M | 159.3M |
| Profitability Metrics | |||||
| EBITDA | (251.2M) | (350.9M) | (331.4M) | (414.4M) | (371.8M) |
| D&A | 45.0M | 47.3M | 43.6M | 33.1M | 21.1M |
| EBIT | (296.2M) | (398.2M) | (375.0M) | (447.5M) | (392.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026